TY - JOUR
T1 - Multidisciplinary Treatment for Squamous Cell Carcinoma of the Anal Canal
AU - Karasawa, Hideaki
AU - Ohnuma, Shinobu
AU - Watanabe, Kazuhiro
AU - Tsuchiya, Takahiro
AU - Imoto, Hirofumi
AU - Aoki, Takeshi
AU - Kudoh, Katsuyoshi
AU - Tanaka, Naoki
AU - Nagao, Munenori
AU - Abe, Tomoya
AU - Musha, Hiroaki
AU - Motoi, Fuyuhiko
AU - Kamei, Takashi
AU - Naito, Takeshi
AU - Unno, Michiaki
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Chemoradiotherapy(CRT)has been recognized as a standard treatment for locoregional squamous cell carcinoma of the anal canal in Western countries. However, surgery had historically been considered as a standard treatment and there are only a few reports on CRT for anal canal cancer in Japan. In this study, we analyzed medical records of 5 anal canal cancer patients treated with CRT in our hospital between 2005 and 2015. Patients' characteristics were as follows: median age, 70 years (range 42-80 years); male/female, 1/4; and clinical Stage I / III a/ III b, 3/1/1. The regimens of chemotherapy were MMC plus 5-FU in 4 patients and CDDP in 1 patient. The median follow-up period was 30 months(range, 6 to 100 months). After CRT, 4 patients achieved complete response. The other patient with partial response underwent salvage surgery. All patients were alive without recurrence. In conclusion, our retrospective study showed that CRT is considered to be a standard treat- ment for anal canal cancer.
AB - Chemoradiotherapy(CRT)has been recognized as a standard treatment for locoregional squamous cell carcinoma of the anal canal in Western countries. However, surgery had historically been considered as a standard treatment and there are only a few reports on CRT for anal canal cancer in Japan. In this study, we analyzed medical records of 5 anal canal cancer patients treated with CRT in our hospital between 2005 and 2015. Patients' characteristics were as follows: median age, 70 years (range 42-80 years); male/female, 1/4; and clinical Stage I / III a/ III b, 3/1/1. The regimens of chemotherapy were MMC plus 5-FU in 4 patients and CDDP in 1 patient. The median follow-up period was 30 months(range, 6 to 100 months). After CRT, 4 patients achieved complete response. The other patient with partial response underwent salvage surgery. All patients were alive without recurrence. In conclusion, our retrospective study showed that CRT is considered to be a standard treat- ment for anal canal cancer.
UR - http://www.scopus.com/inward/record.url?scp=85046410013&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046410013&partnerID=8YFLogxK
M3 - Article
C2 - 29394850
AN - SCOPUS:85046410013
SN - 0385-0684
VL - 44
SP - 2009
EP - 2010
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 12
ER -
